Clinical Trial Update: Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating image-guided IMRT with cetuximab for locoregionally confined recurrent head and neck squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Squamous Cell Cancer of the Head and Neck | Phase 2 | Status: WITHDRAWN